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Abstract
Hyperglycemia-induced oxidative stress plays a key role in the onset/progres-
sion of cardiovascular diseases. For example, it can trigger formation of
advanced glycation end (AGE) products with ischemia-reperfusion performed
under hyperglycemic conditions. For this study, we hypothesized that albumin
modified by glycation loses its unique cardioprotective properties in the set-
ting of ischemia-reperfusion under high glucose conditions. Here, ex vivo rat
heart perfusions were performed under simulated normo- and hyperglycemic
conditions, that is Krebs-Henseleit buffer containing 11 mmol/L and
33 mmol/L glucose, respectively,  normal or glycated albumin preparations.
The perfusion protocol consisted of a 60 min stabilization step that was fol-
lowed by 20 min of global ischemia and 60 min reperfusion. Additional
experiments were completed to determine infarct sizes in response to 20 min
regional ischemia and 120 min reperfusion. At the end of perfusions, heart
tissues were isolated and evaluated for activation of the AGE pathway, oxida-
tive stress, and apoptosis. Our data reveal that native bovine serum albumin
treatment elicited cardioprotection (improved functional recovery, decreased
infarct sizes) under high glucose conditions together with enhanced myocar-
dial antioxidant capacity. However, such protective features are lost with gly-
cation where hearts displayed increased infarct sizes and poor functional
recovery versus native albumin treatments. Myocardial antioxidant capacity
was also lowered together with activation of the intracellular AGE pathway.
These data therefore show that although albumin acts as a cardioprotective
agent during ischemia-reperfusion, it loses its cardioprotective and antioxidant
properties when modified by glycation.
Introduction
Cardiovascular diseases (CVD) due to hyperglycemia are
a leading cause of mortality (Mulnier et al. 2006). This
poses a significant health burden as the global prevalence
of diabetes is surging (Mbanya et al. 2010). There is a
growing interest to better understand the association
between hyperglycemia and CVD, for example, acute
myocardial infarction (AMI) (Soedamah-Muthu et al.
2006; Gardner 2014; Martın-timon et al. 2014). There is a
robust link between chronic hyperglycemia and macrovas-
cular complications (Marcovecchio et al. 2011), with AMI
a major factor leading to higher deaths within the diabetic
context (Kannel et al. 1974; Diabetes Control and Com-
plications Trial Research Group, 1993; United Kingdom
Prospective Diabetes Study, 1998). Damaging effects also
occur in the acute setting, with stress-induced hyper-
glycemia linked to in-hospital deaths, cardiogenic shock,
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2017 | Vol. 5 | Iss. 2 | e13107
Page 1
Physiological Reports ISSN 2051-817X
and congestive heart failure (Capes et al. 2000; Sleiman
et al. 2008; Marfella et al. 2009). Moreover, several rea-
sons, for example, undiagnosed diabetes, impaired glucose
tolerance (Norhammar et al. 2002; Sawin and Shaugh-
nessy 2010), and stress-mediated responses (Capes et al.
2000; Marfella et al. 2009) are put forward to explain the
onset of hyperglycemia in persons that do not suffer from
diabetes.
With both acute and chronic hyperglycemia, there is
increased reactive oxygen species (ROS) production that
activates similar metabolic and signaling pathways that
mediate cardiac tissue damage (Marcovecchio et al. 2011;
Mapanga and Essop 2016). Moreover, hyperglycemia-
induced oxidative stress originates from various processes
such as excessive production of oxygen radicals from glu-
cose autoxidation and mitochondrial respiration, glycoxi-
dized proteins, and glycoxidation of antioxidative
proteins (Li et al. 2007; Folli et al. 2011; Mapanga and
Essop 2016). Collective data from biochemical, animal,
and epidemiological studies support the hypothesis that
glycoxidative modification of circulating proteins plays a
pivotal and causative role in the pathogenesis of cardio-
metabolic diseases (Guerin-Dubourg et al. 2012; Essop
2016).
Albumin is the most abundant serum protein with a
wide range of biological properties (normal concentra-
tions in range: 35–50 g/L) and is also susceptible to
glycoxidative modification that may alter its structure
and function (Francis 2010). Albumin is a highly sol-
uble protein that contains 585 amino acids with a
molecular weight of 66 kDa (Roche et al. 2008). This
allows it to exert beneficial effects with the onset of
various pathophysiologic conditions, for example, albu-
min can protect against ischemia-reperfusion injury
(Watts and Maiorano 1999; Robinet et al. 2007). There
is ample evidence suggesting that albumin exerts signifi-
cant antioxidant activity (Roche et al. 2008) and that it
represents the predominant circulating antioxidant
molecule that is therefore exposed to continuous stress
(Phillips et al. 1989; Luoma et al. 1995). For example,
hyperglycemia results in albumin glycation by the
nonenzymatic attachment of glucose molecules to free
primary amine residues that eventually leads to the
formation of advanced glycation end products (AGE)
[reviewed in Mapanga & Essop (2016)]. The formation
and accumulation of AGEs constitute a characteristic
feature of cardio-metabolic complications; an effect they
exert directly on the cells (Mullarkey and Edelstein
1990) or via interaction with the receptor for advanced
glycation end products (RAGE) (Neeper et al. 1992;
Yan et al. 1994). Binding of such ligands to RAGE
induces intracellular signal transduction, leading to
the activation of several proinflammatory pathways
(Bierhaus et al. 2001; Zieman and Kass 2004; Yonekura
et al. 2005). Thus, RAGE acts, at least in part, as an
activator of carbonyl stress and is implicated in various
cardio-metabolic disorders (Sell et al. 1992).
Epidemiological studies established an inverse rela-
tionship between serum albumin levels and mortality
risk; this is also the case with CVD (Phillips et al.
1989; Luoma et al. 1995). We previously reported on
the damaging effects of increased myocardial AGE for-
mation with ex vivo ischemia-reperfusion performed
under simulated hyperglycemic conditions (Mapanga
et al. 2014). As glycated albumin can result in cardiac
dysfunction during ischemia-reperfusion by interfering
with the beta 1 adrenoreceptor (Robinet et al. 2007),
we hypothesized that albumin glycation results in loss
of its cardioprotective properties during ischemia-reper-
fusion under conditions of simulated acute hyper-
glycemia.
Materials and Methods
Synthesis and validation of glycated bovine
serum albumin (BSAgly)
For this part, we tested the glycation on both BSA and
human serum albumin (HSA). However, no subsequent
experiments were carried out using HSA. BSA
(Sigma-Aldrich, St. Louis MO) was prepared separately
at 40 g/L in 19 PBS and filtered. The solutions were
subsequently divided into two components, the first
native part and the second part which was glycated
using 40% methyglyoxal solution at a final concentra-
tion of 10 mmol/L, filtered and dialysed. The native
BSA was used for control experiments, whereas the gly-
cated BSA was subsequently quantified (to final concen-
tration of 0.01 mmol/L in the perfusate). We evaluated
the success of BSA or HSA glycation by measuring
fructosamine (product of glycation) levels using the
method developed by Johnson et al. (1983) by employ-
ing the nitroblue tetrazolium reagent. The protocol was
described in a previous study from our group (Guerin-
Dubourg et al. 2012). Results are expressed as mmol/L
of 1-deoxy-1-morpholinofructose which is a synthetic
ketoamine used as a primary standard. Furthermore,
the levels of free amine groups were also quantified
using the 2, 4, 6-trinitrobenzenesulfonic acid assay
(Snyder & Sobocinski, 1975). This method was
described in detail in a previous study by our group
(Rondeau et al., 2010). Various concentrations of L-gly-
cine (10–200 nmol) were used to define the standard
curve. In addition, molecular weights of both glycoxi-
dized and non-glycoxidized samples were determined by
mass spectrometry.
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Animals and ethics statement
The Animal Ethics Committee of Stellenbosch University
approved this study and rats were treated in accordance
with the Guide for the Care and Use of Laboratory Ani-
mals of the National Academy of Sciences (NIH publica-
tion No. 85-23, revised 1996).
Ex vivo perfusion protocol
Male Wistar rats (180–220 gr) were employed for all
experiments and after anesthetized (pentobarbitone,
100 mg/kg i.p.) hearts were swiftly excised for perfusion
studies. Here, we used a modified Langendorff model
(Mapanga et al. 2014) with Krebs-Henseleit buffer con-
taining (in mmol/L) 11 Glucose, 118 NaCl, 4.7 KCl, 1.2
MgSO4.7H2O, 2.5 CaCl2.2H2O, 1.2 KH2PO4, 25
NaHCO3 was equilibrated with 95% O2-5% CO2 (37°C,
pH 7.4) at a constant pressure (100 cm of H2O). The
hearts were permitted to beat at its natural rate and buf-
fer was not recirculated. A latex balloon (attached to
pressure transducer) (Stratham MLT 0380/D, ADInstru-
ments Inc, Bella Vista NSW, Australia) was put into the
left ventricle. This was carefully executed via the mitral
valve and the balloon thereafter inflated to generate sys-
tolic and diastolic pressures of 80–120 and 4–12 mm
Hg, respectively. The perfusion pressure was maintained
at approximately 70–80 mmHg during the stabilization
period. We also employed a heated water jacket to
ensure that the temperature for perfused hearts was con-
sistently maintained at 37°C for the entire duration of
the experimental protocol.
Hearts were randomly distributed into six experimental
groups: control (11 mmol/L glucose)  native BSA or
BSAgly; and high glucose (33 mmol/L)  BSA or BSAgly
(n = 6 rats per group). As ex vivo Langendorff perfusions
are normally performed with 11 mmol/L glucose, we sim-
ulated acute hyperglycemia by employing a 33 mmol/L
glucose concentration, a threefold increase. Perfusing with
glycated albumin in the high glucose groups was included
to elucidate its effects per se in control groups and in
combination with high glucose.
Ex vivo global ischemia and reperfusion
during simulated acute hyperglycemia
Here, a 60 min stabilization period was followed by
20 min of global ischemia and 60 min reperfusion. The
following functional parameters were evaluated: heart rate
(HR), left ventricular developed pressure (LVDP), end
diastolic pressure (EDP), rate-pressure product (RPP =
HR 9 LVDP), and coronary flow. In addition, we also
determined the postischemic percentage recovery for
LVDP, velocity of contraction (dP/dt), and RPP. In this
case, we expressed reperfusion values as a percentage of
preischemic data points. The coronary flow was also eval-
uated by pooling perfusion effluent at specific times. After
the reperfusion stage, left and right ventricular tissues
were rapidly collected by freeze-clamping and subse-
quently stored at 80°C for additional analyses.
Ex vivo regional ischemia and reperfusion
during simulated acute hyperglycemia
To strengthen the contractile functional data, the effects
of BSA and BSAgly on infarct size were also assessed
(20 min regional ischemia, 120 min reperfusion); infarct
size and area-at-risk were determined as described before
(Mapanga et al. 2012, 2014). Briefly, a 3/0 silk suture was
placed around the proximal portion of the left anterior
descending coronary artery and suture ends passed
through a plastic tube to form a snare. For induction of
regional ischemia, the snare was occluded and after
20 min, it was released to initiate reperfusion. The effi-
cacy of ischemia was confirmed by regional cyanosis and
a substantial decrease in coronary flow. After completion
of each regional ischemia and reperfusion experiment, the
snare was retightened and 2.5% Evans blue dye (in Krebs
buffer) was perfused through hearts for identification of
the area at risk of ischemia. Hearts were subsequently
removed from the Langendorff apparatus, blotted dry,
suspended (using suture) within 50 mL plastic tubes, and
frozen at 20°C for 3 days. Thereafter, frozen hearts were
sliced into 2 mm transverse sections and incubated with
1% 2,3,5-triphenyl tetrazolium chloride (TTC) in phos-
phate-buffered saline for 20 min at 37°C to distinguish
noninfarcted (stained) from infarcted (nonstained) tis-
sues. The area that was not stained with Evans Blue was
defined as the area at risk (AAR). The area that displayed
neither blue nor red was defined as the infarct site. Slices
were then fixed in 10% formalin for 24 h at room tem-
perature before being placed between glass plates for scan-
ning for preparation of the phosphate-buffered saline).
We determined infarct size and the AAR by employing
Image J software (v1.46p, National Institutes of Health,
USA). For this study, the infarct size is expressed as a
percentage of the AAR.
Measurement of tissue AGE and
fructosamine-3-kinase (FN3K) concentrations
We employed commercial ELISA kits to assess the
myocardial concentrations of AGE (Cell Biolabs, San
Diego CA) and FN3K (Cusabio, Baltimore MD) in
heart tissue lysates, according to the manufacturer’s
instructions.
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Western blot analysis
After global ischemia, we isolated left and right ventricu-
lar tissues for homogenization and thereafter protein
extraction and immunoblotting were performed with rep-
resentative markers for: apoptosis repressor with caspase
recruitment domain (ARC; Sigma-Aldrich, St. Louis
MO); AGEs, RAGE; superoxide dismutase 1 and 2
(SOD1, SOD2) (all from Abcam, Cambridge MA). Stan-
dard densitometric analysis was employed to quantify
blotting data and we used b-actin (Cell Signaling, Dan-
vers MA) as a control for loading (Mapanga et al., 2012).
Statistical analysis
All the data obtained were nonparametric, therefore, statis-
tical analysis was performed by the Mann-Whitney t-test to
compare between two groups. Kruskal-Wallis one-way
analysis of variance (ANOVA) followed by the Dunns post
hoc test (GraphPad Prism v5, San Diego CA) was used to
compare means of three or more groups. Data are
presented as mean  standard error of mean (SEM) and
values were considered significant when P < 0.05.
Results
Validation of BSA glycation
The initial experiments validated the success of BSA and
HSA glycation with the high-molecular-weight AGEs.
Figure 1 also shows that BSA glycation was more successful
versus HSA glycation and therefore only BSA data are
provided. BSA glycation is indicated by increased fruc-
tosamine levels in the BSAgly versus BSA groups (343  27
vs. 39  15 nmol/mmol BSA, P < 0.05) (Fig. 1A). This
result was mirrored by decreased levels of free amine in
the BSAgly group from 36  1 to 12  1 nmol/nmol
BSA (P < 0.05 vs. native BSA, Fig. 1B). Furthermore,
our data revealed increased molecular mass for BSA
glycation versus the native BSA groups (P < 0.05, Fig. 1C
and D).
Impairment of cardiac contractile function
under high glucose conditions and by BSAgly
Hearts exposed to high glucose perfusate displayed
decreased cardiac contractile function following
Figure 1. Validation of BSA glycation as indicated by the concentration of (A) fructosamine, (B) free amine and (C) levels of BSA and BSAgly
and (D) quantification of the protein mass of BSA and BSAgly. Values are expressed as mean  SEM (n = 6). * P < 0.05 versus respective
controls.
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ischemia-reperfusion versus baseline glucose conditions.
This was reflected by a significant decrease in the %
LVDP recovery and dP/dtmax in the high glucose versus
control groups (Fig. 2A and B). RPP followed the same
trend, however, there were no differences in the heart rate
and coronary flow rate (data not shown). Neither BSA
nor BSAgly treatment caused significant effects on heart
function in response to ischemia-reperfusion under
control conditions (11 mmol/L glucose) (Fig. 2C and D).
However, under high glucose conditions, BSA administra-
tion improved functional recovery versus BSAgly with a %
LVDP recovery of 36  7 versus 25  4 (P < 0.05),
respectively, at the end of the reperfusion period
(Fig. 2E). Likewise, the % dP/dtmax recovery was signifi-
cantly improved with native BSA treatment versus BSAgly
(Fig. 2F).
Figure 2. Cardiac contractile function following global ischemia and reperfusion as indicated by (A) % left ventricular developed pressure
(LVDP) and (B) % dP/dtmax recovery under baseline and acute high glucose conditions; % LVDP recovery with native bovine serum albumin
(BSA) versus glycated albumin (BSAgly) under (C) baseline and (D) acute high glucose conditions; % dP/dtmax recovery (E) under baseline and (F)
acute high glucose conditions with native bovine serum albumin (BSA) versus glycated albumin (BSAgly). Values are expressed as mean  SEM
(n = 6). * P < 0.05 versus respective controls.
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Infarct size and apoptosis are elevated in
the BSAgly-treated high glucose groups
These data also revealed increased infarct size under high
glucose perfusion conditions, that is from 45  2% to
58  4% (P < 0.05 vs. 11 mmol/L glucose control,
Fig. 3A). As stated earlier, the administration of native
BSA or BSAgly did not result in any significant effect on
infarct sizes for the control groups. By contrast, treatment
with BSA decreased infarct size versus the untreated high
glucose group under high glucose perfusion conditions
(P < 0.05). However, this protective effect was lost with
glycation as BSAgly further increased infarct size to
65  3% versus 58  4% in the high glucose untreated
group (P < 0.05, Fig. 3A).
Myocardial AGE levels and markers of AGE
metabolism are elevated by BSAgly under
high glucose perfusion conditions
We next assessed markers of myocardial AGE levels and
metabolism as potential mediatory mechanisms that may
play a role in the observed functional changes. Myocardial
AGE formation was increased with ischemia-reperfusion
under high glucose versus controls (P < 0.05) (Fig. 3B).
Moreover, BSAgly administration resulted in a further ele-
vation of AGE formation under these experimental condi-
tions (P < 0.01), while native BSA attenuated AGE
formation (P < 0.01) (Fig. 3B). Myocardial levels of
FN3K were elevated by high glucose perfusions, while this
was further increased by BSAgly administration (P < 0.001
Figure 3. The effects of native bovine serum albumin (BSA) versus glycated albumin (BSAgly) on (A) infarct sizes (regional ischemia) and
advanced glycation end product (AGE) pathway activation as indicated by: (B) AGE levels, (C) fructosamine-3-kinase (FN3K) levels, (D) receptor
for advanced glycation end product (RAGE) expression. Values are expressed as mean  SEM (n = 6). * P < 0.05, ** P < 0.01, *** P < 0.001
versus respective controls.
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vs. BSA) (Fig. 3C). Protein expression of RAGE was
increased by BSAgly in the control glucose groups
(P < 0.05 vs. control, Fig. 3D), while high glucose perfu-
sions did not significantly alter these levels when com-
pared to controls. In addition, high glucose hearts
perfused with both native BSA and BSAgly, respectively,
showed a significant increase in myocardial RAGE expres-
sion (Fig. 3D).
Superoxide dismutase 1 and 2 expression is
enhanced by native BSA perfusions in the
high glucose setting
Tissue expression of SOD1 and SOD2 was unchanged
with BSA and BSAgly treatments, respectively, in the con-
trol and high glucose groups (Fig. 4A and B). The expres-
sion of both markers were, however, upregulated in the
native BSA-treated groups exposed to high glucose
(P < 0.05 BSA vs. BSAgly for SOD1; P < 0.05 BSA vs.
high glucose and BSAgly, respectively, for SOD2). We also
assessed myocardial apoptosis by evaluating ARC (an
apoptosis inhibitor) levels and found an increase in BSA-
treated hearts under high glucose conditions (P < 0.05 vs.
high glucose control, Fig. 4C). There were no significant
changes in the control glucose groups, while perfusion
with BSAgly also did not affect ARC expression in the
high glucose group.
Discussion
This study revealed that the cardioprotective effect of
native albumin is lost upon glycation in hearts exposed to
ischemia-reperfusion under (simulated) acute hyper-
glycemic conditions. In line with our previous findings,
high glucose exposure per se resulted in impaired heart
function and this was associated with larger infarct sizes,
Figure 4. Albumin glycation following ischemia-reperfusion under acute high glucose conditions results in decreased (A) superoxide dismutase
(SOD1) and (B) SOD2 protein expression levels and also lower antiapoptotic (C) apoptosis repressor with caspase recruitment domain (ARC)
protein levels. Values are expressed as mean  SEM (n = 6). *P < 0.05 versus respective controls.
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apoptosis, and increased myocardial AGE levels (Mapanga
et al. 2014). Neither BSA nor BSAgly elicited any effects
on most of the experimental parameters measured
under control glucose conditions, suggesting that such
effects are only triggered in the context of high glucose
availability.
Our data also show higher myocardial AGE levels when
perfused hearts (exposed to high glucose) were treated
with BSAgly. There are at least three possibilities whereby
detrimental effects occur in this instance: (1) glycated
albumin is still taken up by target cells but cannot exert
its usual intracellular antioxidant role due to the struc-
tural modifications; and/or (2) glycated albumin binds to
RAGE on target cells and trigger downstream effects to
increase oxidative stress, AGE generation and inflamma-
tion; and/or (3) the glycation of BSA changes the binding
capacity of this transporter protein, rendering it ineffec-
tive to carry circulating metabolites (Rondeau and Bour-
don 2011). As this study revealed increased myocardial
FN3K activity together with higher AGE levels under high
glucose perfusion conditions, it supports the notion that
downstream intracellular signaling is activated in this
instance. In support, intracellular glycated proteins are
physiological substrates of F3NK (Delpierre and Van
Schaftingen 2003). RAGE expression was also increased
under both control and high glucose experimental condi-
tions with BSAgly treatment, indicating this pathway likely
involved in downstream damaging effects. However,
others found that BSA glycation did not affect RAGE
levels (Deluyker et al. 2016). The precise reasons for this
remain unclear but it is likely due to variations in experi-
mental protocols (in vivo vs. ex vivo); the duration of
glycation exposure and the presence of ischemia and
reperfusion. It is possible that RAGE may be involved in
a temporal manner, that is active during the early stages
following exposure to BSA glycation but that with pro-
longed exposure, there is a shift to RAGE-independent
pathways. However, these possibilities require further
investigations to confirm its validity. Of note, cardiac
RAGE levels showed no significant changes under high
glucose conditions compared to controls. As AGE levels
were increased with high glucose, a positive feedback
effect would be predicted to also lead to higher RAGE
levels. The reason for this finding remains unclear and
requires further investigation with analysis of additional
markers such as soluble RAGE (sRAGE) and high mobil-
ity group box 1 (HMGB1). It is also possible that we
obtained these results since both ventricles were analyzed
instead of only the ischemic tissue. Here, others found
that RAGE upregulation occurs in the ischemic and not
in the nonischemic remote zone (Bucciarelli et al. 2006).
We recently proposed that higher oxidative stress under
hyperglycemic conditions (with ischemia-reperfusion)
may play a central role by triggering damaging down-
stream effects, that is increasing AGEs that can also fuel
inflammation and apoptosis (Mapanga and Essop 2016).
The current findings establish that BSA treatment under
such experimental conditions offered cardioprotection by
augmenting antioxidant capacity. The precise mechanism
(s) whereby such changes occur remain unknown
although it is likely that BSA exerts intracellular antioxi-
dant effects as demonstrated by increased SOD1 and
SOD2 expression levels. In support, albumin taken up by
target cells can elicit antioxidant effects [reviewed in
Francis (2010)]. However, it is unclear whether this is the
case for cardiomyocytes, although albumin can be taken
up by endothelial cells (Francis 2010). These same effects
are, however, not observed under baseline glucose condi-
tions and this possibly occurs as glycation levels are not
high enough to cause significant oxidative stress to trigger
SOD activation.
Limitations of the study
It would have added additional insights if we evaluated
additional markers that relate to the AGE-RAGE pathway,
for example, sRAGE. In addition, although we assessed
expression of markers of oxidative stress, these data
would have been supported by additional enzyme activity
assays such as catalase and SOD, and also actual levels of
various species of oxidative stress.
Conclusions
In summary, this study established that glycation
abolished albumin-mediated cardio-protection with ische-
mia-reperfusion under high glucose conditions and this
centers around the loss of antioxidant capacity and
increased activation of the AGE pathway together with
elevated apoptosis.
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